No Data
No Data
Express News | Protara Therapeutics Inc: In Tara-002, Favorable Safety & Tolerability Profile With No Grade 2 or Greater Treatment-Related Adverse Events
Protara Therapeutics Shares Soar on Positive Data for Bladder Cancer Treatment Trials
Protare Therapeutics Shares Are Trading Higher After the Company Announced Results From Its Ongoing Phase 2 TARA-002 Trial in Patients With NMIBC.
Investors Await Jobless Claims Data as Markets Tread Water in Thursday's Premarket
Express News | Protara Therapeutics Shares up 48.9% Premarket After Co Reports Mid-Stage Data for Bladder Cancer Therapy
Protara Therapeutics Announces Results From Phase 2 ADVANCE-2 Trial
No Data